ThePeptide Examiner
Subscribe
Editorial team
ThePeptide Examiner

Who writes and reviews this publication.

The Peptide Examiner is produced by an editorial team responsible for fact-checking every claim against primary literature and regulatory filings. This page will expand to named individual bylines as contributors are formalized.

Editor-in-chief

Editorial direction, final publish authority, and responsibility for corrections sits with the publication's editor-in-chief. Contact via editor@thepeptideexaminer.com.

Medical review

At present this site uses editorial review, not medical review. We verify claims against primary sources (PubMed, ClinicalTrials.gov, FDA.gov, federal register) but no licensed physician or pharmacist holds formal authority over every published page. Articles carry an Editorially reviewed byline until a named medical reviewer is retained.

Retaining a named PharmD or MD reviewer is on our near-term roadmap. When it happens, applicable pages (every peptide pillar, every comparison page, the FDA tracker, every GLP-1 deep dive) will carry the reviewer's name, credentials, and review date in a dedicated reviewer block.

What our team specializes in

  • Peptide pharmacology and mechanism
  • GLP-1 receptor agonist clinical trials and regulatory actions
  • FDA compounding law (503A, 503B, Category 1/2/3)
  • Longevity and regenerative peptide research
  • FTC endorsement guidelines and affiliate compliance

Conflicts of interest

The editorial team does not own equity in, consult for, or receive direct payments from any peptide vendor or manufacturer. The publication earns revenue exclusively from (a) affiliate relationships with FDA-approved telehealth providers and vetted compounding pharmacies, disclosed inline on every page that contains them, and (b) reader subscriptions (when launched). We will update this section if any team member's outside interests change.

Contact the team